MedTech M&A activity rebounded in the second quarter of 2026, with 113 announced transactions, up 36% from the first quarter. Strategic acquirers accounted for approximately 60% of transactions as buyers pursued businesses that complement their capabilities and growth priorities.
PMCF Investment Banking Director Mike Brooks spoke with Modern Healthcare about the recovery and how greater clarity around trade policy and regulatory conditions is helping buyers move forward.
How Trade Policy and Reimbursement Risks Affect MedTech M&A
Tariffs and reimbursement risks continue to influence transaction decisions. However, improved predictability is helping buyers assess those exposures and determine how to address them.
“We’ve been working on deals that have been impacted by trade policy, tariff rates, reimbursement risks,” Brooks told Modern Healthcare. “Those are still impacting deals to some extent, but the volatility around macro and regulatory environments is starting to narrow a little bit, giving buyers more confidence to move forward.”
For owners considering a transaction, greater clarity does not remove the need for preparation. Buyers continue to scrutinize manufacturing footprints and supply chains, making tariff exposure and mitigation strategies important diligence topics.
Why Medical Device Contract Manufacturers Attract Buyers
Medical device contract development and manufacturing organizations (CDMOs) are also attracting attention. As Brooks explained, some increasingly serve as strategic partners, supporting medical devices from prototyping and design through high-volume production. These capabilities are particularly relevant in cardiovascular, minimally invasive surgical and orthopedic applications.
Read Mike Brooks’ comments in Modern Healthcare for more on the factors shaping MedTech deal activity.
Learn more about PMCF’s Healthcare and MedTech M&A practice.
Authors
More Articles
Selling a Roofing Company: What Buyers Look For
For owners considering selling a roofing company, acquisition activity is only part of the picture. The more important question is how buyers will evaluate the business — and what will distinguish it from other acquisition opportunities.
Building Value Ahead of a Distribution M&A Transaction
Distribution M&A remains active in 2026, but buyers are becoming more selective about the businesses they pursue and the attributes that warrant premium valuations.
Building Products M&A: Differentiation, Consolidation and the Data Center Opportunity
The building products sector continues to consolidate as strategic acquirers and private equity investors pursue businesses with differentiated products, strong market positions, and exposure to long-term growth drivers. But the companies creating the most value aren’t always the biggest.
What Packaging Business Owners Should Know About Today’s M&A Market
Packaging M&A continues to attract interest from strategic buyers and private equity investors, even as rising input costs, sustainability requirements, and broader economic uncertainty shape transaction decisions.
Medical Device M&A Remains Active as Buyers Prioritize Quality Over Volume
While MedTech M&A activity has slowed from prior peaks, buyers remain active for the right opportunities.